ST. LOUIS, Feb. 28, 2023 /PRNewswire/ Geneoscopy, a developer of innovative diagnostics for gastrointestinal health, announced the appointment of Don Hardison to its board of directors. Mr. Hardison joins Geneoscopy’s Board of Directors with over 40 years of executive leadership experience in emerging and Fortune 500 diagnostics, biotechnology and life sciences companies.

Mr. Hardison served as president and CEO of Biotheranostics until its acquisition by Hologic in February 2021. Before that, he served as president, CEO, and director at Good Start Genetics. Mr. Hardison also held the position of president and CEO of Exact Sciences from 2000-2007, where he helped oversee the company’s initial public offering. His career includes multiple senior leadership positions at companies such as Labcorp.

“We are excited to welcome Don to our Board at this pivotal point in Geneoscopy’s evolution,” stated Andrew Barnell, Chief Executive Officer and Geneoscopy’s co-founder. “As an accomplished executive  in our industry, Don’s expertise and insights will be valuable in guiding our efforts to bring innovative, noninvasive diagnostics for gastrointestinal health to the providers and patients who will benefit the most.”

For the past two years, Mr. Hardison has served as a strategic advisor to Geneoscopy. In his new role as a board member, Mr. Hardison will help guide Geneoscopy as it prepares for commercialization of its lead offering, a noninvasive, stool-based, at-home screening test to detect colorectal cancer and advanced adenomas in average-risk individuals. This past January, Geneoscopy submitted a Premarket Approval (PMA) application to the U.S. Food and Drug Administration for its test based on the favorable results from the pivotal CRC-PREVENT trial. 

“As an advisor to Geneoscopy for the past two years, I have been impressed by its progress in executing its strategy. I am pleased to join Geneoscopy’s board at such an exciting time for the company, ” said Mr. Hardison. “The recent submission of the PMA – the Company’s first regulatory approval application – represents a significant milestone, and I look forward to supporting Geneoscopy’s commercial strategy as their momentum accelerates.”


About Geneoscopy Inc.

Geneoscopy Inc. is a life sciences company focused on developing diagnostic tests for gastrointestinal health. Leveraging its proprietary, patented stool-derived eukaryotic RNA (seRNA) biomarker platform, Geneoscopy’s mission is to empower patients and providers to transform gastrointestinal health through innovative diagnostics. Beyond colorectal cancer screening, Geneoscopy is developing tests for diagnosis, treatment selection, and therapy monitoring in other disease areas in partnership with leading universities and biopharmaceutical companies. For more information, visit and follow the company on LinkedIn.


Geneoscopy Inc. Forward-Looking Statements

This release includes information about Geneoscopy’s future plans concerning its noninvasive molecular test that can detect colorectal cancer and precancerous adenomas, which constitute forward-looking statements. These forward-looking statements are based on the Company’s reasonable estimates of future results or trends. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict, many of which are outside the Company’s control. Geneoscopy’s actual results and financial condition may differ materially from those in the forward-looking statements. Although the Company believes its business plans and objectives reflected in or suggested by these forward-looking statements are reasonable, such plans or objectives may not be achieved. The actual results may differ substantially from the projected result.